CA-EV-CONNECT
21.5.2024 12:01:29 CEST | Business Wire | Press release
With 5.7 million electric vehicles (EVs) anticipated to be used in fleet applications by 2025, EV Connect, a leading EV charging business platform, and bp pulse, a global leader in charging infrastructure for fleets and public charging, today announced a collaboration to bring key capabilities of Omega, bp pulse's EV charge management software, to the EV Connect platform. Tailored to the diverse charging requirements and duty cycles of EV fleets, Omega delivers a comprehensive managed charging solution that integrates state-of-the-art charging management technology from EV Connect and bp pulse into a new, comprehensive fleet offering.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521725993/en/
The collaboration gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization. (Graphic: Business Wire)
With bp pulse and EV Connect’s Omega integration, fleet operators can focus on their core business while Omega orchestrates charging schedules, prioritizes charging based on fleet needs, and enables real-time insights for informed decision-making, whether charging at depots, on the go, or at driver homes. The collaboration between bp pulse and EV Connect gives fleet operators greater control over charging infrastructure while reducing costs associated with energy consumption and providing detailed historical data for further optimization.
"At bp pulse, we remain steadfast in our mission to simplify electrification for diverse fleets, and collaborating with EV Connect on this endeavor marks an exciting milestone, expanding our scope to deliver turnkey solutions for fleet operators industry-wide," said Sujay Sharma, CEO of bp pulse Americas. “Our shared goal is to provide fleet customers with a comprehensive solution that addresses all aspects of their charging needs—no matter the location. This collaboration allows us to combine our unique offerings into one cohesive platform."
Omega orchestrates EV charging to optimize cost-effective charging for fleets, while the EV Connect platform focuses on managing financial transactions, particularly in commercial fleet settings. This includes fleet operations in which drivers bring vehicles home, requiring private chargers with simple reimbursement options. By combining the capabilities of Omega and the EV Connect platform, fleet operators, including those in government, municipal, logistics, services, and sales sectors, can expect improved efficiency and optimization of their charging stations while empowering fleet managers with precise control over when and how their vehicles are charged, optimizing for factors like energy cost, power constraints, vehicle readiness, and operational efficiency.
"This collaboration between EV Connect and bp pulse brings unparalleled expertise in the electric vehicle charging industry, opening doors to elevate our fleet management capabilities and deliver cutting-edge solutions that set new standards for both of our customers," said Jon Leicester, Vice President and Head of Commercial at EV Connect. "By integrating our platforms, we can offer a comprehensive management solution that caters to fleet operators looking to optimize electric fleet efficiency like never before."
EV Connect is the conduit to accelerating EV charging business growth with technology and tools that drive innovation to fuel new business models in e-mobility. To learn more about how EV Connect is helping businesses of all sizes unlock the power of EV charging business models, please visit www.evconnect.com.
About EV Connect
EV Connect is the all-in-one EV charging platform that delivers the tools to build, run, and scale EV charging businesses successfully. The platform serves a broad set of use cases for customers, including Charge Point Operators (CPOs), charging network providers, Fortune 500 companies, charging business upstarts and trailblazers, fleet-scale transportation providers, and electric utilities.
EV Connect customers benefit from a combination of cutting-edge software features with premium service experiences, such as branded customer support, EV charging station procurement, deployment and installation support, and the latest driver app technology. Because technology, public policy, and technical standards constantly evolve and change, EV Connect has built its platform and tools to ensure that an investment in electric vehicle charging equipment delivers exceptionally reliable performance, confidence in station utilization and revenue management, and return on investment. Founded in 2010, EV Connect offers the tools and connections for EV charging businesses of any size, with the power of an open-platform approach and a trusted partner network.
For more information, please visit www.evconnect.com and follow us on X and LinkedIn.
About bp pulse
bp pulse is bp’s electric vehicle (EV) charging business, rolling out fast, reliable charge points to consumers and commercial fleets around the world. Globally, bp pulse is one of the UK’s leading rapid and ultra-fast public EV charging networks. It also operates the largest number of sites with ultra-fast charging in Germany, with a growing charging point footprint in China and the Netherlands. The company aims to increase its network of public EV charging points by 2030 to over 100,000 worldwide.
bp pulse is bp’s electric vehicle (EV) charging business. Focused on fast and reliable charging, bp pulse deploys charging points for EV drivers and commercial fleets on the go; at destination hubs, at the depot and bp retail sites. Around the world bp pulse is working with some of the world’s biggest businesses, while developing the Gigahub™ network, a series of large EV high-speed charging hubs in high-demand locations. Electric vehicle charging is one of five growth engines of bp’s transformation into an integrated energy company. The company has already installed more than 27,000 charge points and aims to expand its network of public EV charging stations to more than 100,000 worldwide by 2030. In the US, bp is planning to invest up to $1 billion in EV charging by 2030. For more information, visit bppulsefleet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521725993/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom